An evolving vaccine market fueled by rapid innovation has shifted channels for vaccine distribution and administration, […]
As companies with global commercialization aspirations move from clinical development to launch, it becomes important to […]
BIO-Europe Spring connects Europe’s top innovation centers with the global life sciences industry to cultivate thriving […]
ClearView Healthcare Partners Makes Strategic Investment in Epistemic AI to Advance Next-Generation Biomedical AI Platform ClearView […]
From a population health perspective, the need to more effectively treat neurological dysfunction is pressing, as […]
GLP-1 receptor agonists are already reshaping people and healthcare systems for the management of obesity. Treatment paradigms in cardiovascular disease, sleep apnea and MASH are set to be disrupted, but it is not all gravy; weight loss post GLP-1s is often not maintained and not everyone can tolerate their side effects. We share our perspectives on the outlook for the space, including some of the implications for biopharma, service providers and investors.
Radioligand therapies (RLTs) are an emerging class of targeted therapies that could transform the way some cancers are treated. The RLT market is expected to grow significantly over the course of this decade, however several challenges will need to be overcome if the market is to achieve its full potential. In this white paper we consider the scientific, clinical, and commercial requirements for success.
Treatment paradigms in oncology are constantly evolving with more precise and efficacious therapies. One modality with strong potential are mRNA therapeutics which represent a significant growth area and could transform the way some cancers are treated. In this white paper we explore the potential for mRNA to transform the oncology landscape, considering the scientific, clinical and commercial requirements for success
How life sciences companies can use affiliations data to track non-traditional healthcare services.
Psychedelic-assisted therapies with MDMA and psilocybin are poised to transform the treatment options for a variety […]
An exploration within the growing CDMO space of manufacturing capabilities and efficiencies that support development of […]
ClearView Healthcare Partners, the leading life sciences strategic consultancy supporting Pharma and Biotech globally, is excited […]
This August, ClearView Healthcare Partners had the pleasure of welcoming Laurel Sweeney and Andy Molnar for a panel discussion on the challenges and strategic approaches to secure reimbursement for digital health technologies – thank you to both for participating!
• GHO partnering with existing management team to accelerate global growth
• ClearView positioned as market leader in an industry experiencing strong tailwinds
• Management to pursue international markets and broaden service offering, leveraging GHO’s unparalleled sector expertise
ClearView Healthcare Partners, a strategy consulting firm focused in the life sciences, announces the opening of two new offices in London and Zurich, which will strengthen the company's partnerships with both European-based and global life science organizations.
What are the key features of a propriety diagnostic tool that would enable isolation of a unique market opportunity? What is the business model that should be deployed to incentivize investment in this type of tool? In this paper, we will outline the answers to these questions and provide some examples of exciting technologies which may tap this potential.
Exploration of the value potential of digital therapeutics across biopharma portfolios to help companies gain a competitive edge
We have watched in pain, anger, and frustration at the events unfolding across the nation. George […]
With COVID-19, BioPharma companies building out commercial teams are facing a reckoning: How will sales reps […]
San Francisco, CA January 13 – 16, 2020 The ClearView leadership team will be attending […]
Current state and future trajectory of digital health including the actionable ways in which digital health can be uniquely leveraged to fill voids in the healthcare system